<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680758</url>
  </required_header>
  <id_info>
    <org_study_id>VICC BRE 0770</org_study_id>
    <secondary_id>VU-VICC-BRE-0770</secondary_id>
    <nct_id>NCT00680758</nct_id>
  </id_info>
  <brief_title>Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I Study of Cisplatin, Paclitaxel, and RAD001 Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Giving more than one drug (combination chemotherapy) together with&#xD;
      everolimus may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of cisplatin,&#xD;
      paclitaxel, and everolimus when given together for the treatment of patients with metastatic&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To establish the safety profile and the maximum tolerated dose of the combination of&#xD;
           cisplatin, paclitaxel, and everolimus in patients with metastatic breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To explore the antitumor activity of this regimen, in terms of response rate and time to&#xD;
           progression in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive cisplatin intravenously (IV) over 1 hour and paclitaxel IV over 1 hour on&#xD;
      days 1, 8, and 15. Patients receive oral everolimus on days 1, 8, 15, and 21. Courses repeat&#xD;
      every 4 weeks in the absence of disease progression and unaccepted toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed at 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile and maximum tolerated dose</measure>
    <time_frame>At 4 weeks</time_frame>
    <description>The Maximum Tolerated Dose (MTD) will be the dose level at which fewer than 2 of 6 (or 33% of) patients experience dose limiting toxicity (DLT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>Date of study entry to date of progression of disease</time_frame>
    <description>Cisplatin + Paclitaxel + RAD001 combination by determining response rates (RR) and time to progression (TTP) achieved with treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>at baseline and every 8 weeks to disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>date of study entry to date of disease progression</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Dose Level: -3 20mg/m2/week 3-6 patients&#xD;
Dose Level: -2 20mg/m2/week 3-6 patients&#xD;
Dose Level: -1 25mg/m2/week 3-6 patients&#xD;
Dose Level: 1 25mg/m2/week 3-6 patients&#xD;
Dose Level: 2 25mg/m2/week 3-6 patients&#xD;
Dose Level: 3 25mg/m2/week 3-6 patients</description>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>Dose Level: -3 20mg/m2/week 3-6 patients&#xD;
Dose Level: -2 20mg/m2/week 3-6 patients&#xD;
Dose Level: -1 20mg/m2/week 3-6 patients&#xD;
Dose Level: 1 20mg/m2/week 3-6 patients&#xD;
Dose Level: 2 25mg/m2/week 3-6 patients&#xD;
Dose Level: 3 30mg/m2/week 3-6 patients</description>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Dose Level: -3 65mg/m2/week 3-6 patients&#xD;
Dose Level: -2 70mg/m2/week 3-6 patients&#xD;
Dose Level: -1 70mg/m2/week 3-6 patients&#xD;
Dose Level: 1 80mg/m2/week 3-6 patients&#xD;
Dose Level: 2 80mg/m2/week 3-6 patients&#xD;
Dose Level: 3 80mg/m2/week 3-6 patients</description>
    <arm_group_label>Therapeutic Intervention</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive mammary carcinoma&#xD;
&#xD;
               -  Stage IV disease&#xD;
&#xD;
          -  No locally recurrent breast cancer&#xD;
&#xD;
          -  Patients with HER2/neu overexpressing tumors must have received prior trastuzumab&#xD;
             (Herceptin®) in first-line treatment of metastatic breast cancer&#xD;
&#xD;
          -  Patients with estrogen receptor- or progesterone receptor-expressing tumors must have&#xD;
             received prior endocrine therapy (i.e., aromatase inhibitors, fulvestrant, tamoxifen,&#xD;
             or ovarian ablation) in first-line treatment of metastatic breast cancer&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
               -  Patients with a history of brain metastases must be clinically stable and not&#xD;
                  taking steroids or therapeutic anticonvulsants that are CYP3A4 modifiers&#xD;
&#xD;
               -  Patients with asymptomatic brain metastases on prophylactic convulsants that are&#xD;
                  CYP3A4 modifiers are not eligible&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  ANC ≥ 1000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN (3 times ULN if liver metastasis present)&#xD;
&#xD;
          -  SGOT and SGPT ≤ 1.5 times ULN (3 times ULN if liver metastasis present)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN if liver metastasis present&#xD;
&#xD;
          -  Able to swallow and retain oral medication&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Must be disease-free from prior invasive cancers for &gt; 5 years with the exception of&#xD;
             completely resected basal cell or squamous cell carcinoma of the skin or successfully&#xD;
             treated cervical carcinoma in situ&#xD;
&#xD;
          -  No malabsorption syndrome, disease significantly affecting gastrointestinal function,&#xD;
             or ulcerative colitis&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to:&#xD;
&#xD;
               -  Ongoing or active infection requiring parenteral antibiotics&#xD;
&#xD;
               -  Impairment of lung function (i.e., chronic obstructive pulmonary disease or lung&#xD;
                  conditions requiring oxygen therapy)&#xD;
&#xD;
               -  Symptomatic New York Heart Association class III-IV congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within&#xD;
                  the past 6 months&#xD;
&#xD;
               -  Uncontrolled hypertension (systolic blood pressure [BP] &gt; 180 mm Hg or diastolic&#xD;
                  BP &gt; 100 mm Hg)&#xD;
&#xD;
               -  Clinically significant cardiac arrhythmia (i.e., multifocal premature ventricular&#xD;
                  contractions, bigeminy, trigeminy, or ventricular tachycardia that is symptomatic&#xD;
                  or requires treatment)&#xD;
&#xD;
               -  Uncontrolled diabetes&#xD;
&#xD;
               -  Psychiatric illness/social situations that would preclude compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  No known history of uncontrolled or symptomatic neuropathy ≥ grade 2&#xD;
&#xD;
          -  No hypersensitivity to paclitaxel, or drugs using the vehicle Cremophor, Chinese&#xD;
             hamster ovary cell products, or other recombinant human antibodies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from all prior treatment&#xD;
&#xD;
          -  Must not have exceeded a total cumulative dose of life-time exposure of doxorubicin&#xD;
             hydrochloride ≤ 360 mg/m² or epirubicin hydrochloride ≤ 640 mg/m²&#xD;
&#xD;
          -  At least 2 weeks since other prior investigational drugs&#xD;
&#xD;
          -  No prior resection of the stomach or small bowel&#xD;
&#xD;
          -  No more than 4 prior chemotherapy regimens in the metastatic setting&#xD;
&#xD;
               -  This restriction does not include endocrine therapies or single agent biologic&#xD;
                  therapies (i.e., trastuzumab)&#xD;
&#xD;
          -  Concurrent radiotherapy to painful bone metastases or areas of impending bone fracture&#xD;
             allowed as long as radiotherapy is initiated prior to study entry&#xD;
&#xD;
          -  No concurrent trastuzumab&#xD;
&#xD;
          -  No concurrent endocrine therapy&#xD;
&#xD;
          -  No concurrent CYP3A4 modifiers&#xD;
&#xD;
          -  No concurrent herbal supplement&#xD;
&#xD;
          -  No other concurrent anticancer therapy (chemotherapy, radiotherapy, surgery,&#xD;
             immunotherapy, hormonal therapy, or biological therapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingrid Mayer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center - Cool Springs</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center at Franklin</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center at Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>May 18, 2008</study_first_submitted>
  <study_first_submitted_qc>May 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2008</study_first_posted>
  <last_update_submitted>March 7, 2013</last_update_submitted>
  <last_update_submitted_qc>March 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Ingrid Mayer, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine; Clinical Director, Breast Cancer Program; Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>male breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

